Details for New Drug Application (NDA): 211732

NDA 211732 describes OMEPRAZOLE MAGNESIUM, which is a drug marketed by Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, L Perrigo Co, Spil, Aurobindo Pharma, Hetero Labs Ltd Iii, P And L, and Perrigo R And D, and is included in eight NDAs. It is available from forty-nine suppliers. Additional details are available on the OMEPRAZOLE MAGNESIUM profile page.

The generic ingredient in OMEPRAZOLE MAGNESIUM is omeprazole magnesium. There are one hundred and thirty-one drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the omeprazole magnesium profile page.

Summary for 211732

Tradename:	OMEPRAZOLE MAGNESIUM
Applicant:	Hetero Labs Ltd Iii
Ingredient:	omeprazole magnesium
Patents:	0

Pharmacology for NDA: 211732

Mechanism of Action

Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

Suppliers and Packaging for NDA: 211732

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
OMEPRAZOLE MAGNESIUM	omeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	211732	ANDA	A-S Medication Solutions	50090-6888	50090-6888-0	2 BOTTLE in 1 CARTON (50090-6888-0) / 14 TABLET, DELAYED RELEASE in 1 BOTTLE
OMEPRAZOLE MAGNESIUM	omeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	211732	ANDA	Camber Consumer Care Inc	69230-318	69230-318-05	500 TABLET, DELAYED RELEASE in 1 BOTTLE (69230-318-05)

Profile for product number 001

Active Rx/OTC/Discontinued:	OTC	Dosage:	TABLET, DELAYED RELEASE;ORAL			Strength	EQ 20MG BASE
Approval Date:	Mar 25, 2020	TE:		RLD:	No

Complete Access Available with Subscription